

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, DC 20549

---

**SCHEDULE 13D**

Under the Securities Exchange Act of 1934  
(Amendment No. 3\*)

---

**Axovant Sciences Ltd.**

(Name of Issuer)

Common Shares, \$0.0001 par value per share  
(Title of Class of Securities)

G0750W104  
(CUSIP Number)

Dexxon Holdings Ltd.  
1 Dexcel Street  
Or Akiva, 3060000, Israel  
+972-4-6364040

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

March 18, 2019  
(Date of Event Which Requires Filing of This Statement)

---

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

---

**Note:** Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

---

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

---

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

---

---

1.	Name of reporting person Dexxon Holdings Ltd.	
2.	Check the appropriate box if a member of a group (a) <input type="checkbox"/> (b) <input type="checkbox"/>	
3.	SEC use only	
4.	Source of funds OO – other	
5.	Check box if disclosure of legal proceedings is required pursuant to Item 2(e) or 2(f) <input type="checkbox"/>	
6.	Citizenship or place of organization Israel	
Number of shares beneficially owned by each reporting person with	7.	Sole voting power 0
	8.	Shared voting power 0
	9.	Sole dispositive power 0
	10.	Shared dispositive power 105,952,381 Common Shares (see Item 5)
11.	Aggregate amount beneficially owned by each reporting person 105,952,381 Common Shares (see Item 5)	
12.	Check box if the aggregate amount in Row (11) excludes certain shares <input type="checkbox"/>	
13.	Percent of class represented by amount in Row (11) 58.2% (see Item 5)*	
14.	Type of reporting person CO	

\* The calculation assumes that there are a total of 182,194,438 Common Shares outstanding, as reported by Axovant Sciences Ltd. (the "Issuer") in its prospectus supplement filed with the SEC on March 15, 2019.

1.	Name of reporting person Dexcel Pharma Technologies Ltd.	
2.	Check the appropriate box if a member of a group (a) <input type="checkbox"/> (b) <input type="checkbox"/>	
3.	SEC use only	
4.	Source of funds OO – other	
5.	Check box if disclosure of legal proceedings is required pursuant to Item 2(e) or 2(f) <input type="checkbox"/>	
6.	Citizenship or place of organization Israel	
Number of shares beneficially owned by each reporting person with	7.	Sole voting power 0
	8.	Shared voting power 0
	9.	Sole dispositive power 0
	10.	Shared dispositive power 105,952,381 Common Shares (see Item 5)
11.	Aggregate amount beneficially owned by each reporting person 105,952,381 Common Shares (see Item 5)	
12.	Check box if the aggregate amount in Row (11) excludes certain shares <input type="checkbox"/>	
13.	Percent of class represented by amount in Row (11) 58.2% (see Item 5)*	
14.	Type of reporting person CO	

\* The calculation assumes that there are a total of 182,194,438 Common Shares outstanding, as reported by the Issuer in its prospectus supplement filed with the SEC on March 15, 2019.

1.	Name of reporting person Dan Oren	
2.	Check the appropriate box if a member of a group (a) <input type="checkbox"/> (b) <input type="checkbox"/>	
3.	SEC use only	
4.	Source of funds OO – other	
5.	Check box if disclosure of legal proceedings is required pursuant to Item 2(e) or 2(f) <input type="checkbox"/>	
6.	Citizenship or place of organization Israel	
Number of shares beneficially owned by each reporting person with	7.	Sole voting power 0
	8.	Shared voting power 0
	9.	Sole dispositive power 0
	10.	Shared dispositive power 105,952,381 Common Shares (see Item 5)
11.	Aggregate amount beneficially owned by each reporting person 105,952,381 Common Shares (see Item 5)	
12.	Check box if the aggregate amount in Row (11) excludes certain shares <input type="checkbox"/>	
13.	Percent of class represented by amount in Row (11) 58.2% (see Item 5)*	
14.	Type of reporting person IN	

\* The calculation assumes that there are a total of 182,194,438 Common Shares outstanding, as reported by the Issuer in its prospectus supplement filed with the SEC on March 15, 2019.

**EXPLANATORY NOTE**

This Amendment No. 3 (the "Amendment") amends and supplements the Schedule 13D filed by the Reporting Persons on July 8, 2016, as amended by Amendment No. 2 thereto on December 20, 2018 and Amendment No. 1 thereto on June 7, 2018 (the "Schedule 13D"). Except as specifically provided herein, this Amendment does not modify any of the information previously reported in the Schedule 13D. Capitalized terms used but not otherwise defined in this Amendment shall have the same meanings ascribed to them in the Schedule 13D.

**ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION**

Item 3 of the Schedule 13D is hereby amended and supplemented as follows:

The 105,952,381 Common Shares reported herein are directly owned by Roivant Sciences Ltd. ("Roivant"). The Issuer, prior to its initial public offering on June 11, 2015, was a wholly-owned subsidiary of Roivant.

On March 18, 2019, upon the closing of the Issuer's underwritten public offering of Common Shares conducted pursuant to a registration statement on Form S-3 (the "Offering"), Roivant purchased 6,666,667 Common Shares from the underwriters of the Offering at the public offering price of \$1.50 per share. Roivant purchased the Common Shares using cash on hand.

To the extent required by Item 3, the information set forth or incorporated in Items 4 and 5 is hereby incorporated herein by reference.

---

**ITEM 4. PURPOSE OF TRANSACTION.**

Item 4 of the Schedule 13D is hereby amended and supplemented by the following information:

The Reporting Persons are filing this Amendment because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the 105,952,381 Common Shares of the Issuer held by Roivant by virtue of governance arrangements in Roivant's bye-laws. The Reporting Persons do not directly own any Common Shares. The Reporting Persons understand that Roivant purchased the 6,666,667 Common Shares in the Offering to maintain Roivant's investment in the Issuer following the Offering. The Reporting Persons understand that, as the Issuer's majority shareholder, Roivant may provide additional financing to the Issuer from time to time in the form of an investment in equity or debt securities of the Issuer or loans, including in connection with business development transactions or financing commitments in relation thereto.

**ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.**

Item 5 of the Schedule 13D is hereby amended and supplemented by the following information:

- (a) – (b) The Common Shares are directly beneficially owned by Roivant. The Reporting Persons may be deemed to have shared dispositive power, and therefore, beneficial ownership, over the 105,952,381 Common Shares owned directly by Roivant. Roivant's bye-laws provide Dexion and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares (the "Override Right"). Each of Dexion and DPT is a shareholder of Roivant and, collectively, are holders of the Override Right. Voting and dispositive decisions of Dexion are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexion and DPT. Accordingly, Dan Oren may be deemed to have investment and voting control over the Common Shares held by Roivant.

The percentage of outstanding Common Shares that may be deemed to be beneficially owned by each Reporting Person is set forth on line 13 of the cover sheet of this Schedule 13D. Such percentage was calculated based on an aggregate of 182,194,438 Common Shares issued and outstanding, as reported in the Issuer's prospectus supplement filed with the SEC on March 15, 2019.

Except as disclosed in this Amendment, each Reporting Person does not have the right to acquire any Common Shares, and does not presently have the power to vote or to direct the vote or to dispose or direct the disposition of any of the Common Shares that the Reporting Person may be deemed to beneficially own.

Each of the Reporting Persons disclaims beneficial ownership in all of the Common Shares reported herein, except to the extent of the Reporting Person's respective pecuniary interest therein. The filing of this Amendment shall not be construed as an admission that the Reporting Persons are, for the purposes of Section 13(d) or 13(g) of the Securities Exchange Act of 1934, as amended, the beneficial owners of the Common Shares.

---

**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

Dated: March 19, 2019

/s/ Dan Oren

Dan Oren

DEXXON HOLDINGS LTD.

By: /s/ Dan Oren

Name: Dan Oren

Title: Director

DEXCEL PHARMA TECHNOLOGIES LTD.

By: /s/ Dan Oren

Name: Dan Oren

Title: President and Chief Executive Officer

---